254 related articles for article (PubMed ID: 25302481)
1. Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study.
Desai RJ; Eddings W; Liao KP; Solomon DH; Kim SC
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):457-66. PubMed ID: 25302481
[TBL] [Abstract][Full Text] [Related]
2. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
[TBL] [Abstract][Full Text] [Related]
3. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
[TBL] [Abstract][Full Text] [Related]
4. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
Kim G; Barner JC; Rascati K; Richards K
J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
[TBL] [Abstract][Full Text] [Related]
6. The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.
Wu CY; Chen DY; Shen JL; Ho HJ; Chen CC; Kuo KN; Liu HN; Chang YT; Chen YJ
Arthritis Res Ther; 2014 Sep; 16(5):449. PubMed ID: 25267341
[TBL] [Abstract][Full Text] [Related]
7. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
[TBL] [Abstract][Full Text] [Related]
8. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski M; Farley J
J Rheumatol; 2014 Nov; 41(11):2129-36. PubMed ID: 25086079
[TBL] [Abstract][Full Text] [Related]
10. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
Ozen G; Pedro S; Holmqvist ME; Avery M; Wolfe F; Michaud K
Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
[TBL] [Abstract][Full Text] [Related]
11. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
[TBL] [Abstract][Full Text] [Related]
12. Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis.
Desai RJ; Solomon DH; Schneeweiss S; Danaei G; Liao KP; Kim SC
Epidemiology; 2016 May; 27(3):414-22. PubMed ID: 26808597
[TBL] [Abstract][Full Text] [Related]
13. Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis.
Kawai VK; Grijalva CG; Arbogast PG; Curtis JR; Solomon DH; Delzell E; Chen L; Ouellet-Hellstrom R; Herrinton L; Liu L; Mitchel EF; Stein CM; Griffin MR
Arthritis Care Res (Hoboken); 2011 Oct; 63(10):1415-24. PubMed ID: 22121511
[TBL] [Abstract][Full Text] [Related]
14. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis.
Bili A; Tang X; Pranesh S; Bozaite R; Morris SJ; Antohe JL; Kirchner HL; Wasko MC
Arthritis Care Res (Hoboken); 2014 Mar; 66(3):355-63. PubMed ID: 24023053
[TBL] [Abstract][Full Text] [Related]
16. Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study.
Kim SC; Schneeweiss S; Liu J; Karlson EW; Katz JN; Feldman S; Solomon DH
Arthritis Rheumatol; 2016 Sep; 68(9):2106-13. PubMed ID: 27015113
[TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine and Risk of Long QT Syndrome in Rheumatoid Arthritis: A Veterans Cohort Study With Nineteen-Year Follow-up.
Quiñones ME; Joseph JK; Dowell S; Moore HJ; Karasik PE; Fonarow GC; Fletcher RD; Cheng Y; Zeng-Treitler Q; Arundel C; Liappis AP; Sheriff HM; Zhang S; Taub DD; Heimall MS; Faselis C; Kerr GS; Ahmed A
Arthritis Care Res (Hoboken); 2023 Jul; 75(7):1571-1579. PubMed ID: 36039941
[TBL] [Abstract][Full Text] [Related]
18. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data.
Steffen A; Holstiege J; Klimke K; Akmatov MK; Bätzing J
Rheumatol Int; 2018 Nov; 38(11):2111-2120. PubMed ID: 30306254
[TBL] [Abstract][Full Text] [Related]
19. Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study.
Kang EH; Jin Y; Tong AY; Desai RJ; Kim SC
Arthritis Care Res (Hoboken); 2020 Oct; 72(10):1383-1391. PubMed ID: 31376333
[TBL] [Abstract][Full Text] [Related]
20. Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
Sparks JA; Krumme AA; Shrank WH; Matlin OS; Brill G; Pezalla EJ; Choudhry NK; Solomon DH
Arthritis Rheumatol; 2016 Jul; 68(7):1588-95. PubMed ID: 26866506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
